The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options.

Younossi, Zobair; Stepanova, Maria; Sanyal, Arun J; Harrison, Stephen A; Ratziu, Vlad; Abdelmalek, Manal F; Diehl, Anna Mae; Caldwell, Stephen; Shiffman, Mitchell L; Schall, Raul Aguilar; McColgan, Bryan; Subramanian, G Mani; Myers, Robert P; Muir, Andrew; Afdhal, Nezam H; Bosch, Jaime; Goodman, Zachary (2018). The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options. Journal of hepatology, 69(6), pp. 1365-1370. Elsevier 10.1016/j.jhep.2018.08.013

Text 1-s2.0-S0168827818322955-main.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (522kB)

BACKGROUND & AIMS

Although patients with cryptogenic cirrhosis have historically been considered as having "burnt-out" non-alcoholic steatohepatitis (NASH), some controversy remains. The aim of this study was to compare outcomes of patients with cryptogenic cirrhosis and NASH-related cirrhosis from a cohort with longitudinal follow-up data.

METHODS

Patients with cryptogenic cirrhosis or NASH cirrhosis were screened for a clinical trial. Patients with <5% hepatic steatosis regardless of other histologic features were considered to have cryptogenic cirrhosis. Clinico-laboratory data and adjudicated liver-related events (e.g. decompensation, qualification for transplantation, death) were available.

RESULTS

A total of 247 patients with cirrhosis (55.3 ± 7.4 years, 37% male) were included; 144 had NASH cirrhosis and 103 had cryptogenic cirrhosis. During a median follow-up of 29 (IQR 21-33) months (max 45 months), 20.6% of patients had liver-related clinical events. Patients with NASH cirrhosis and cryptogenic cirrhosis were of a similar age and gender, as well as having a similar body mass index, PNPLA3 rs738409 genotype, and prevalence of diabetes (p >0.05). However, patients with cryptogenic cirrhosis had higher serum fibrosis markers and greater collagen content and α-smooth muscle actin expression on liver biopsy. Compared to cirrhotic patients with NASH, patients with cryptogenic cirrhosis experienced significantly shorter mean time to liver-related clinical events (12.0 vs. 19.4 months; p = 0.001) with a hazard ratio of 1.76 (95% CI 1.02-3.06).

CONCLUSIONS

Populations with NASH and cryptogenic cirrhosis have similar demographics, but patients with cryptogenic cirrhosis have evidence of more active fibrosis and a higher risk of liver-related clinical events. Thus, we believe these patients belong to the same spectrum of disease, with cryptogenic cirrhosis representing a more advanced stage of fibrosis.

LAY SUMMARY

Significant liver damage and cirrhosis of the liver may develop without a known cause - a liver disease referred to as cryptogenic cirrhosis. In this work we found that, in the presence of metabolic abnormalities, cryptogenic cirrhosis may actually be a part of the non-alcoholic fatty liver disease spectrum. Yet, it appears to be more progressive than typical non-alcoholic fatty liver disease, leading to advanced liver disease at a faster rate.

Interest & Impact

Downloads

2 since deposited on 17 Dec 2018
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item